RESVINET
  • Home
  • About RSV
    • professionals
    • Publications
  • about us
    • The foundation
    • ReSViNET Team
    • contact us >
      • Support us >
        • Webshop
        • Donate
  • Conference
    • RSVVW'23
    • Previous conferences >
      • RSVVW'21
      • RSVVW'19
      • 4th Meeting 2017
      • 3rd Meeting 2017
      • 2nd Expert Meeting
      • 1st Expert Meeting
  • Webinar Series
  • patient network
    • Activities >
      • Webinars
    • RSV Awareness Week
    • Patient Advisory Board
    • Promise
    • RSV reading material
    • contact patient network
  • Home
  • About RSV
    • professionals
    • Publications
  • about us
    • The foundation
    • ReSViNET Team
    • contact us >
      • Support us >
        • Webshop
        • Donate
  • Conference
    • RSVVW'23
    • Previous conferences >
      • RSVVW'21
      • RSVVW'19
      • 4th Meeting 2017
      • 3rd Meeting 2017
      • 2nd Expert Meeting
      • 1st Expert Meeting
  • Webinar Series
  • patient network
    • Activities >
      • Webinars
    • RSV Awareness Week
    • Patient Advisory Board
    • Promise
    • RSV reading material
    • contact patient network

Publications

Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection

26/10/2020

0 Comments

 
Habibi MS, Thwaites RS, Chang M, Jozwik A, Paras A, Kirsebom F, Varese A, Owen A, Cuthbertson L, James P, Tunstall T, Nickle D, Hansel TT, Moffatt MF, Johansson C, Chiu C, Openshaw PJM

​Why does RSV exposure in one individual lead to disease, while another individual does not experience symptoms at all? Besides, how can a virus reinfect individuals that already have a specific viral immune response available? In this Science paper, Habibi and his colleagues present mucosal neutrophil activation as a new factor involved in RSV susceptibility and protection. They studied the nasal mucosa by transcriptional and proteomic analyses in 58 healthy volunteers right before RSV inoculation and during the following days of infection. An active neutrophilic inflammatory status in the airways at the time of viral exposure was found to predispose to symptomatic infection. This effect might be mediated by a reduction in antiviral inflammatory responses directly after viral exposure. In addition, an early immune response to the infection with enriched IL-17 signaling and corresponding pathways was associated with protection from RSV-related symptoms. Further experiments in mice showed that chemokine induced neutrophil recruitment to the airway before viral exposure enhances disease severity and leads to an elevated cytotoxic CD8+ T cell response. These findings shed light on mechanisms of viral susceptibility and suggest new targets for RSV intervention. Furthermore, neutrophilic inflammation of the airways might not only be important in RSV infection, but in other viral respiratory diseases as well, such as in the SARS-CoV-2 infection. 
​
Download paper of the month | October 2020
0 Comments

    CATEGORIES

    All
    ReSViNET Publications


    ARCHIVES

    March 2023
    January 2023
    April 2022
    February 2022
    September 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    March 2020
    January 2020
    December 2019
    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    April 2018
    December 2017
    May 2017
    March 2017
    February 2017
    September 2016
    June 2016
    March 2016
    November 2015
    October 2015
    September 2015
    June 2015
    May 2015
    April 2015
    March 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014


    RSS Feed

Note: All information on ReSViNET is for educational purposes only. For specific medical advice, diagnoses, and treatment, consult your doctor.

© 2021 ReSViNET Foundation. All rights reserved.
About us
Disclosure
Contact